drugset / Trial / NCT06658535
A Dose Escalation Study of NanO2 in Patients With Mild Respiratory Distress
Non-randomizedSequentialOpen-labelTreatment
Summary
EXTEND is a dose escalation study of NanO2™ in patients with mild respiratory distress who are at risk for mechanical ventilation. The study will establish dosing guidelines for a Phase 2 study.
Timeline
- Start
- 2025-03-13
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PERFLENAPENT | Small molecule | 0.375 unknown | Intravenous |
| Subject | PERFLENAPENT | Small molecule | 0.48 unknown | Intravenous |
| Subject | PERFLENAPENT | Small molecule | 0.75 unknown | Intravenous |
Indications
No indication recorded.